Intervention Review

Rivastigmine for Alzheimer's disease

  1. Jacqueline Birks1,*,
  2. John Grimley Evans2,
  3. Vasso Iakovidou3,
  4. Magda Tsolaki4

Editorial Group: Cochrane Dementia and Cognitive Improvement Group

Published Online: 15 APR 2009

Assessed as up-to-date: 8 SEP 2008

DOI: 10.1002/14651858.CD001191.pub2

How to Cite

Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD001191. DOI: 10.1002/14651858.CD001191.pub2.

Author Information

  1. 1

    University of Oxford, Centre for Statistics in Medicine, Oxford, UK

  2. 2

    University of Oxford, Division of Clinical Geratology, Nuffield Department of Clinical Medicine, Oxford, UK

  3. 3

    Thessaloniki, Makedonia, Greece

  4. 4

    Aristotle University of Thessaloniki, 3rd Neurology Department, Thessaloniki, Macedonia, Greece

*Jacqueline Birks, Centre for Statistics in Medicine, University of Oxford, Wolfson College, Linton Road, Oxford, OX2 6UD, UK. jacqueline.birks@csm.ox.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 15 APR 2009

SEARCH

  1. Current Version

    Rivastigmine for Alzheimer's disease

    Jacqueline Birks, John Grimley Evans, Vasso Iakovidou and Magda Tsolaki

    Article first published online: 15 APR 2009 | DOI: 10.1002/14651858.CD001191.pub2

Previous versions of this article and their online publication dates

  1. Version 1

    Rivastigmine for Alzheimer's disease

    Jacqueline Birks, John Grimley Evans, Vasso Iakovidou and Magda Tsolaki

    Article first published online: 23 OCT 2000 | DOI: 10.1002/14651858.CD001191